Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 2/20 | 0.61 |
| ▸ | NCF1 | P14598 | 2/20 | 0.53 |
| ▸ | SLC22A12 | Q96S37 | 5/20 | 0.49 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 4/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.44 |
| ▸ | AKT1 | P31749 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.44 |
| ▸ | CCNC | P24863 | 1/20 | 0.44 |
| ▸ | CDK8 | P49336 | 1/20 | 0.44 |
| ▸ | GAK | O14976 | 1/20 | 0.42 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.42 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.42 |
| ▸ | STK16 | O75716 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.42 |
| ▸ | COQ8A | Q8NI60 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 2-Aminopyridine SCHEMBL28096419 | 0.87 | NCF1 (0.50) | NR4A2NCF1SLC22A12SOS2HTT | |
| SCHEMBL435803 | 0.84 | NR4A2 (0.61) | NR4A2NCF1SLC22A12SOS2HTT | |
| SCHEMBL31285386 | 0.84 | NR4A2 (0.61) | NR4A2NCF1SLC22A12SOS2HTT | |
| SCHEMBL14690611 | 0.79 | SLC22A12 (0.51) | NCF1SLC22A12HTTCHEK1PIM1 | |
| SCHEMBL29896761 | 0.79 | SLC22A12 (0.51) | NCF1SLC22A12HTTCHEK1PIM1 | |
| SCHEMBL4823097 | 0.79 | NR4A2 (0.66) | NR4A2NCF1SLC22A12SOS2HTT | |
| SCHEMBL30210360 | 0.79 | NR4A2 (0.66) | NR4A2NCF1SLC22A12SOS2HTT | |
| Bromide SCHEMBL5989384 | 0.78 | NR4A2 (0.63) | NR4A2NCF1SLC22A12SOS2HTT | |
| SCHEMBL24150113 | 0.76 | NR4A2 (0.61) | NR4A2NCF1SOS2HTTABL1 | |
| SCHEMBL729828 | 0.76 | SLC22A12 (0.49) | NCF1SLC22A12HTTCHEK1PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110756172-B | Inorganic salt hazardous waste recycling treatment process | 内蒙古中泰汇金环保科技有限公司 | 2022-06-07 | — | — | CN | claimed |
| CN-108250232-B | Refining method of bis (diethyl) aminosilane | 浙江博瑞电子科技有限公司 | 2021-03-16 | — | — | CN | claimed |
| CN-110756172-A | Inorganic salt hazardous waste recycling treatment process | 内蒙古中泰汇金环保科技有限公司 | 2020-02-07 | — | — | CN | claimed |
| CN-108250232-A | It is a kind of double（Diethyl）The process for purification of amino silane | 浙江博瑞电子科技有限公司 | 2018-07-06 | — | — | CN | claimed |
| US-20120065166-A1 | Bone Modulators And Methods Therewith | ESPINA VIRGINIA (US) | 2012-03-15 | — | — | US | claimed |
| US-20240239752-A1 | BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-07-18 | — | — | US | disclosed |
| US-20240239752-A1 | BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-07-18 | — | — | US | disclosed |
| US-11926632-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2024-03-12 | — | — | US | disclosed |
| CN-117120419-A | KLK5 bicyclic heteroaromatic inhibitors | 拜奥克里斯特制药公司 | 2023-11-24 | — | — | CN | disclosed |
| CN-116462630-A | Quinoline low-temperature curing agent, polyimide and photosensitive resin | 深圳先进电子材料国际创新研究院 | 2023-07-21 | — | — | CN | disclosed |
| EP-4167982-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV Pharmaceuticals, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| US-20230046427-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-02-16 | — | — | US | disclosed |
| EP-2048142-A2 | Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof | Eisai R&D Management Co., Ltd. (JP) | 2009-04-15 | — | — | EP | disclosed |
| US-20080300239-A1 | QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2008-12-04 | — | — | US | disclosed |
| EP-1382603-B1 | NITROGENOUS FUSED-RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF | EISAI R&D MAN CO LTD (JP) | 2008-07-23 | — | — | EP | disclosed |
| WO-2008051808-A2 | BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-05-02 | — | — | WO | disclosed |
| US-20070225318-A1 | Pyrazole Compounds Useful In The Treatment Of Inflammation | BIOLIPOX AB (SE) | 2007-09-27 | — | — | US | disclosed |
| EP-1794145-A1 | PYRAZOLE COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATION | Biolipox AB (SE) | 2007-06-13 | — | — | EP | disclosed |
| WO-2007039146-A1 | 4-CARBOXY PYRAZOLE DERIVATIVES AS ANTI-VIRAL AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-04-12 | — | — | WO | disclosed |
| WO-2006032851-A1 | PYRAZOLE COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225318-A1 | Pyrazole Compounds Useful In The Treatment Of Inflammation | ALOX15, ALOX15B, ALOX12 | NR4A2 753/4885NCF1 1100/4885SLC22A12 3791/4885 |
| US-20230046427-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, HRAS | NR4A2 2014/4885NCF1 374/4885SLC22A12 3985/4885 |
| US-20240239752-A1 | BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | KLK5, KLK1, KLKB1 | NR4A2 2887/4885NCF1 1687/4885SLC22A12 3531/4885 |
| US-11926632-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, HRAS | NR4A2 2014/4885NCF1 374/4885SLC22A12 3985/4885 |
| US-20080300239-A1 | QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS | PIK3CD, PIK3CG, PIK3CB | NR4A2 3868/4885NCF1 1224/4885SLC22A12 3927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.